Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Refuge Biotechnologies Inc.
Headquarters: Menlo Park, CA, United States of America
Website: N/A
Year Founded: 2015
Status: Out of Business
BioCentury | Oct 21, 2022
Politics, Policy & Law
Oct. 20 Quick Takes: Novartis commits first cancer therapy to UN patent pool
Plus: AbbVie gains LPAR1 antibody via $255M buy of DJS and updates for Denali, the U.K., Kite-Refuge, Takeda-Zedira, Immunic, Talaris, Celeris
BioCentury | Jul 13, 2022
Emerging Company Profile
Epic Bio: Epigenome editing via compact components
Horizons Ventures leads $55M series A for start-up developing compact epigenome editors with all-in-one AAV delivery
BioCentury | Jun 24, 2022
Data Byte
CAR T cells headline HER2 cell therapy pipeline
CAR T cells are the most popular strategy to hit the solid tumor-selective target, but companies are using at least five other methods
BioCentury | Feb 15, 2022
Management Tracks
Lundbeck’s Williamson joins Avadel as CMO
Plus new CFO at Cellectis, and updates from 2seventy bio, City of Hope, Stablix and more
BioCentury | Nov 25, 2021
Product Development
Next-gen TILs and TCRs face a durability challenge
SITC provides a snapshot of how companies are enhancing TIL and TCR therapies
BioCentury | Oct 19, 2021
Discovery & Translation
CRISPR innovation hits the gas
A burst of research is radically expanding tools to optimize CRISPR therapies and access new targets
BioCentury | Sep 9, 2021
Translation in Brief
Growing list of mini Cas nucleases that fit in gene delivery vectors
Plus: Max Planck, UPenn, Fred Hutch and more
BioCentury | May 17, 2021
Deals
Refuge applies CAR T engineering platform to TILs through MD Anderson deal
And it’s looking for similar deals around NK cells and macrophages
BioCentury | Jan 20, 2021
Management Tracks
Marincola to lead Kite’s cell therapy research; plus moves at T-knife, Applied Molecular Transport, Frequency and NexImmune
Kite Pharma Inc. hired Francesco Marincola as SVP and global head of cell therapy research, effective Feb. 1. Marincola joined the Gilead Sciences Inc. (NASDAQ:GILD) unit from Refuge
BioCentury | Mar 12, 2020
Management Tracks
Hoerr takes helm from Menichella at CureVac; plus Genmab hires Mancini as COO, Tricida, Akcea, Refuge, Adaptate, Thermo Fisher and more
Items per page:
1 - 10 of 15